What Is BPC-157?
Last reviewed:
BPC-157 is a synthetic peptide of 15 amino acids (a “pentadecapeptide”) whose sequence is derived from a protein identified in gastric juice. It is studied in scientific research as a reference compound for investigating tissue-repair and angiogenesis pathways. BPC-157 is an investigational compound and is not an approved medicine.
How is BPC-157 classified and what is its structure?
BPC-157 (“Body Protection Compound-157”) is a stable synthetic pentadecapeptide. Its amino-acid sequence is described in the literature as derived from a fragment of a protein found in gastric juice, and the peptide is reported to be stable in that environment. In the literature it is grouped with peptides studied for roles in cytoprotection and tissue maintenance.
How is BPC-157’s mechanism studied in research?
Published research — much of it preclinical / animal-model — investigates BPC-157 in relation to:
- Growth-factor signalling associated with tissue repair.
- The nitric-oxide (NO) system, studied in vascular and cytoprotection research.
- Angiogenesis (the formation of new blood vessels) in study models.
These statements describe the published scientific record — much of it preclinical / animal-model research — and are not claims about any effect in humans.
What kind of research has been published on BPC-157?
The BPC-157 literature is predominantly preclinical, including animal-model studies of wound healing and angiogenesis and review articles on gastric-pentadecapeptide cytoprotection. A 2025 systematic review in HSS Journal surveyed 36 BPC-157 studies published between 1993 and 2024 — 35 preclinical and one clinical — underlining how heavily the evidence base sits in laboratory models. Findings are reported in the primary scientific literature listed below.
What compounds is BPC-157 studied alongside?
In recent review literature, BPC-157 is most often examined alongside other investigational peptides studied in tissue-repair models — particularly thymosin beta-4 (TB-500), and in broader peptide reviews together with growth-hormone-secretagogue peptides such as CJC-1295 and ipamorelin. These groupings describe how the compounds are classified and reviewed together in the published scientific record; they do not imply equivalence between compounds or any human-use indication.
How is BPC-157 supplied, tested and handled?
Lazarus Labs supplies BPC-157 as a lyophilised reference material, independently tested to 99%+ purity, with a batch Certificate of Analysis (COA). Store cold and protected from light, per standard laboratory practice.
References
- Sikiric P, Hahm KB, Blagaic AB, et al. Gut and Liver. 2020. PMID: 31158953.
- Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in Pharmacology. 2021. PMID: 34267654.
- Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Journal of Physiology and Pharmacology. 2009. PMID: 20388964.
- Vasireddi N, et al. HSS Journal. 2025. PMID: 40756949.
- Mayfield CK, et al. The American Journal of Sports Medicine. 2026. PMID: 41476424.
Primary literature, verified against PubMed/PMC; predominantly preclinical / animal-model. Citations are provided for scientific reference and do not imply any human-use indication.
Important
For research use only. Not for human or veterinary consumption. BPC-157 is an investigational compound and is not an approved therapeutic good. Lazarus Labs supplies it solely as a laboratory reference material and makes no therapeutic, medical or performance claims. Nothing on this page is medical advice or a recommendation to administer this compound to humans or animals.